Lobe Sciences Ltd.

03/31/2026

Lobe Sciences’ latest update also outlines a more capital efficient operating model.

The Company described a subsidiary based structure intended to reduce parent level overhead, share scientific and administrative resources across programs, and allocate capital more efficiently as development efforts advance.

Combined with the Company’s improved financial position, this structure is intended to support disciplined ex*****on across its development programs.

Follow Lobe Sciences for ongoing corporate updates.

03/27/2026

Lobe Sciences’ latest update outlines measurable improvement in the Company’s financial position and capital structure.

Liabilities were reduced by 81%, cash increased more than 24 times, and net working capital improved by approximately $6.1 million. Outstanding warrants were also reduced by about 70%, lowering potential future dilution.

The update reflects a clearer balance sheet and a stronger financial foundation to support disciplined ex*****on.

Follow Lobe Sciences for ongoing corporate updates.

03/18/2026

Last week, Lobe Sciences announced the appointment of its new CFO.

This week’s update focuses on the broader role of financial oversight within the Company’s governance framework. Clear reporting structure, disciplined capital allocation, and consistent oversight remain important to orderly ex*****on and long term shareholder alignment.

Follow Lobe Sciences for ongoing corporate updates.

03/10/2026

Lobe Sciences Ltd. announces the appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer, effective March 2, 2026.

Mr. Rahimani has been advising management and the Board since December 1, 2025 and now assumes the role of CFO.

He brings extensive experience in financial reporting, corporate governance, corporate development, strategic transactions, and public-company compliance.

For additional information regarding this announcement or to connect with the Company, please contact the Lobe Sciences team directly.

CSE: LOBE | OTCQB: LOBEF | FWB: LOBE

03/09/2026

Lobe Sciences Ltd. will be in Miami during the upcoming Jefferies and Leerink Healthcare Conferences.

Chief Executive Officer Dr. Frederick D. Sancilio will be available for meetings with investors, pharmaceutical companies, and organizations interested in learning more about the Company’s development programs.

If you will be attending the conferences and would like to connect with the Lobe Sciences team, we welcome you to reach out to arrange a time to meet.

Will you be attending either conference this week?

03/06/2026

Lobe Sciences Ltd. will be in Miami during the upcoming Jefferies and Leerink Healthcare Conferences.

CEO Dr. Frederick D. Sancilio will be available for meetings with investors, pharmaceutical companies, and organizations interested in learning more about the Company’s development programs and pipeline.

Full announcement:
https://finance.yahoo.com/news/lobe-sciences-ltd-announces-presence-124000832.html

01/10/2026

Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
Read the full press release here: https://lnkd.in/eTrwQ3SD

09/30/2025

Lobe Sciences (CSE: LOBE) spins out Conjugated Psilocin to Cynaptec Pharmaceuticals and closes a US$6M financing, with an option for an additional US$20M.

“This move unlocks the full value of our neurological platform.” – Dr. Fred D. Sancilio, CEO obe Sciences (CSE:LOBE, OTCQB:LOBEF)

ACCESS Newswire is the leading global press release distribution service. Tell your story and reach millions of journalists. Contact us today to get started.

03/21/2025

Launching a new product like Altemia ® Medical Food (MF) involves securing reimbursement pathways from insurers and other third-party payers. Unfortunately, the process for medical food lacks clear guidelines. Each state has its own rules, requiring separate applications for reimbursement approval in 2025. Meanwhile, we are collaborating with several Sickle Cell Disease (SCD) research clinics to gather additional data on the benefits of Altemia ® MF and its impact on this debilitating disease.

03/18/2025

Dr. Fred D. Sancilio (CEO & Board Chairman) and Mr. Rick Goulburn (COO & Board Member) look forward to Day 2 of .

03/14/2025

The 505(b)(2) pathway is widely used by many applicants, if not most, for seeking market approval from the FDA. This pathway allows applicants to reference existing data from other companies that is pertinent to their product. For instance, with L-130, our new psilocin conjugate, we can leverage numerous high-quality publications that provide safety data for psilocybin or psilocin. By combining this existing data with our own research, we can build a compelling case for the safety of psilocin, regardless of the method of ingestion.

​To readdress the question regarding Lobe's utilization of this pathway, we can confidently state that we plan to use this approach if we conclude that it will expedite approval.